中國醫療集團(08225.HK)稱治療新冠特效藥邁可欣原料和製劑開始規模生產
中國醫療集團(08225.HK)公布,3月14日內地衛健委發布《新型冠狀病毒肺炎診療方案(試行第九版)》治療方案,增加PF-07321332/利托那韋,包含集團參與研製的利托那韋,該成分與輝瑞克奈瑪特韋組合,將新冠病毒死亡風險降低89%。早年也是治療愛滋病的雞尾酒治療藥物。
集團指,關聯企業萬全制藥是唯一同時擁有利托那韋原料和製劑企業,邁可欣是中國大陸唯一被批准的利托那韋口服液,集團將長期負責此系列產品的臨床研究,國際註冊和上市後臨床研究RWS式推廣,因此集團將長期從產品組團中獲益。目前原料藥生產已經藥監局復核檢驗獲批,在更大產能基地廈門萬特製藥生產並收到源源不斷訂貨。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.